[Recurrent ovarian cancer with cancer peritonitis treated with weekly paclitaxel infusion--a clinicopharmacological study].
We treated a patient with recurrent ovarian cancer with cancerous peritonitis by weekly paclitaxel (w-TXL) therapy (65 mg/m2). Abdominocentesis was not performed to eliminate ascites, in order to maintain higher quality of life (QOL), and critical adverse reaction was not seen for 12 months. We measured the TXL concentration in blood plasma and ascites after TXL infusion by HPLC method. The TXL titer in plasma was 427 ng/ml after infusion, 23 ng/ml after 24 hours and under 10 ng/ml after 48 hours. The TXL titer in ascites was 41 ng/ml after infusion, 37 ng/ml after 6 hours, 18 ng/ml after 12 hours, 10 ng/ml after 24 hours and under 10 ng/ml after 48 hours. TXL transportation from blood to ascites was good. This result suggested that intravenous infusion of TXL was effective for cancerous peritonitis treatment.
Urabe
Satoshi
S
Dept. of Gynecology, Hiroshima Prefectural Hospital.
Fujiwara
Hisaya
H
Egawa
Makiko
M
Fujitou
Naoya
N
Sakashita
Tomohisa
T
Date
Kenjirou
K
Mizunoe
Tomoya
T
Ueda
Katsunori
K
Urabe
Takeshi
T
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001202:Ascitic Fluid / Q000737:chemistry; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017239:Paclitaxel / Q000008:administration & dosage* / Q000493:pharmacokinetics; D010538:Peritonitis / Q000188:drug therapy*; D011788:Quality of Life
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel